Crescent Biopharma, Inc. Asset Resilience Ratio
Crescent Biopharma, Inc. asset resilience ratio. Crescent Biopharma, Inc. (CBIO) has an Asset Resilience Ratio of 0.01% as of March 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Crescent Biopharma, Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Crescent Biopharma, Inc. (2011–2016)
Asset resilience ratio of Crescent Biopharma, Inc. from 2011 to 2016. This chart shows how Crescent Biopharma, Inc.'s Asset Resilience Ratio has changed over time. Read CBIO current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Crescent Biopharma, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Crescent Biopharma, Inc. (CBIO) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.22K | 0.01% |
| Total Liquid Assets | $5.22K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Crescent Biopharma, Inc. maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Crescent Biopharma, Inc. Industry Peers by Asset Resilience Ratio
Compare Crescent Biopharma, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Crescent Biopharma, Inc. Asset Resilience Ratio by Year (2011–2016)
Crescent Biopharma, Inc. asset resilience ratio by year from 2011 to 2016. The table below shows the annual Asset Resilience Ratio data for Crescent Biopharma, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 0.03% | $10.65K | $42.39 Million | +0.01pp |
| 2015-12-31 | 0.02% | $9.27K | $48.46 Million | -0.01pp |
| 2014-12-31 | 0.03% | $16.29K | $57.26 Million | +0.01pp |
| 2013-12-31 | 0.02% | $1.00K | $5.28 Million | -94.30pp |
| 2012-12-31 | 94.32% | $17.37 Million | $18.42 Million | -3.13pp |
| 2011-12-31 | 97.45% | $28.17 Million | $28.91 Million | -- |
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the develo… Read more